(Q37765900)

22 August 2017

1 reference

title

Emerging drugs for complicated skin and skin-structure infections (English)

1 reference

22 August 2017

Natalia Mendoza

1

1 reference

22 August 2017

Stephen K Tyring

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

Expert Opinion on Emerging Drugs

22 August 2017

published in

1 reference

22 August 2017

volume

15

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

509-520

1 reference

Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Early appropriate parenteral antimicrobial treatment of complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Methicillin-resistant Staphylococcus aureus disease in three communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Skin and soft-tissue infections: impact of resistant gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Health economic issues in the treatment of drug-resistant serious Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Antimicrobial resistance in intensive care units

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Future gazing in the management of multiply drug-resistant Gram-positive infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

The clinical consequences of antimicrobial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Linezolid - the first oxazolidinone in the treatment of nosocomial MRSA pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Update on linezolid: the first oxazolidinone antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

A review of linezolid: the first oxazolidinone antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Linezolid--a review of the first oxazolidinone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Efficacy and safety of linezolid in the treatment of skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Linezolid-resistant methicillin-resistant Staphylococcus aureus isolated after long-term, repeated use of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Polyphyletic emergence of linezolid-resistant staphylococci in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Daptomycin: pharmacology and clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Antibacterial resistance and their genetic location in MRSA isolated in Kuwait hospitals, 1994-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Co-trimoxazole–Sensitive, Methicillin-ResistantStaphylococcus aureus, Israel, 1988–1997

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Evolving epidemiology of pediatric Staphylococcus aureus cutaneous infections in a Baltimore hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Staphylococcus spp. in Spain: present situation and evolution of antimicrobial resistance (1986-2006)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Fusidic acid in vitro activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

An international multicenter study of antimicrobial resistance and typing of hospital Staphylococcus aureus isolates from 21 laboratories in 19 countries or states

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Pharmacokinetics of fusidic acid and cefepime in heart tissues: implications for a role in surgical prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Fusidic acid in skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Fusidic acid adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) by combination with fosfomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Widespread dissemination in The Netherlands of the epidemic berlin methicillin-resistant Staphylococcus aureus clone with low-level resistance to oxacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

United States resistance surveillance results for linezolid (LEADER Program for 2007).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Infections caused by Gram-positive bacteria: a review of the global challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Peptidoglycan structure and architecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Pleiotropic roles of polyglycerolphosphate synthase of lipoteichoic acid in growth of Staphylococcus aureus cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

New screens and targets in antibacterial drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Probing teichoic acid genetics with bioactive molecules reveals new interactions among diverse processes in bacterial cell wall biogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

The N-acetylmannosamine transferase catalyzes the first committed step of teichoic acid assembly in Bacillus subtilis and Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Synthesis of glycerol phosphate lipoteichoic acid in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

A bacteriolytic agent that detects and kills Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Productive steps toward an antimicrobial targeting virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Registered and Investigational Drugs for the Treatment of Methicillin-Resistant Staphylococcus aureus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Mechanism of action of oritavancin and related glycopeptide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.497486

10.1517/14728214.2010.497486

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference